Neumora Therapeutics presents preclinical NMRA-215 data showing up to 19% weight loss in obese mice
NMRA•In obese mice, NMRA-215 produced up to 19% weight loss alone and up to 26% with semaglutide. Neumora said an audit found critical discrepancies in one rat toxicity study, while a second supported clinical development; its NMRA-511 candidate will enter Phase 2 testing for Alzheimer's disease agitation.
1. Obesity candidate data
Neumora Therapeutics presented nonclinical data supporting advancement of NMRA-215 into clinical studies. In obese mice, the candidate produced up to 19% weight loss alone and up to 26% when combined with semaglutide.
2. Safety and agitation studies
One three-month rat toxicity study showed unexpected adverse findings, and an audit identified critical discrepancies; a second study supported clinical development. For Alzheimer's disease agitation, NMRA-511 will enter Phase 2 testing at 20 mg and 30 mg twice daily. Phase 1b showed reduced agitation scores, with larger effects in patients with elevated anxiety, but the study was not powered for statistical significance.




